Reyon Pharmaceutical Co Ltd (KO:102460) — Market Cap & Net Worth
Market Cap & Net Worth: Reyon Pharmaceutical Co Ltd (102460)
Reyon Pharmaceutical Co Ltd (KO:102460) has a market capitalization of $125.41 Million (₩185.06 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18432 globally and #826 in its home market, demonstrating a 0.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Reyon Pharmaceutical Co Ltd's stock price ₩10090.00 by its total outstanding shares 18340991 (18.34 Million). Also see 102460 total assets for a full breakdown of the balance sheet.
Reyon Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Reyon Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $313.77 Million to $125.41 Million (-5.99% CAGR). Also see how efficiently does Reyon Pharmaceutical Co Ltd generate cash for how efficiently the company converts equity into cash flow.
Reyon Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Reyon Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Reyon Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Reyon Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.04x
Reyon Pharmaceutical Co Ltd's market cap is 0.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $243.90 Million | $121.85 Billion | $10.70 Billion | 0.00x | 0.02x |
| 2017 | $238.33 Million | $126.25 Billion | $12.89 Billion | 0.00x | 0.02x |
| 2018 | $160.15 Million | $122.99 Billion | $1.34 Billion | 0.00x | 0.12x |
| 2019 | $188.55 Million | $131.56 Billion | $5.94 Billion | 0.00x | 0.03x |
| 2020 | $268.26 Million | $130.03 Billion | $3.84 Billion | 0.00x | 0.07x |
| 2021 | $434.69 Million | $142.80 Billion | $5.54 Billion | 0.00x | 0.08x |
| 2022 | $266.55 Million | $154.04 Billion | $7.43 Billion | 0.00x | 0.04x |
| 2023 | $205.58 Million | $151.07 Billion | $3.58 Billion | 0.00x | 0.06x |
| 2024 | $159.59 Million | $148.30 Billion | $4.15 Billion | 0.00x | 0.04x |
Competitor Companies of 102460 by Market Capitalization
Companies near Reyon Pharmaceutical Co Ltd in the global market cap rankings as of September 18, 2026. Review Reyon Pharmaceutical Co Ltd (102460) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Reyon Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Reyon Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Reyon Pharmaceutical Co Ltd's market cap moved from $313.77 Million to $ 125.41 Million, with a yearly change of -5.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩125.41 Million | -6.40% |
| 2025 | ₩133.99 Million | -16.04% |
| 2024 | ₩159.59 Million | -22.37% |
| 2023 | ₩205.58 Million | -22.87% |
| 2022 | ₩266.55 Million | -38.68% |
| 2021 | ₩434.69 Million | +62.04% |
| 2020 | ₩268.26 Million | +42.28% |
| 2019 | ₩188.55 Million | +17.73% |
| 2018 | ₩160.15 Million | -32.80% |
| 2017 | ₩238.33 Million | -2.28% |
| 2016 | ₩243.90 Million | -22.27% |
| 2015 | ₩313.77 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Reyon Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $125.41 Million USD |
| MoneyControl | $125.41 Million USD |
| MarketWatch | $125.41 Million USD |
| marketcap.company | $125.41 Million USD |
| Reuters | $125.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more